GLP-1 Medications: How the Body Can React in the Early Stages
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
-
ナレーター:
-
著者:
概要
In this episode, Catriona Williams continues the GLP-1 series with personal trainer Becky Lever, focusing on how the body may respond during the early stages of taking GLP-1 medications.
Together, they discuss commonly reported reactions such as nausea, reduced appetite, digestive changes, fatigue, and brain fog, while emphasising that experiences can vary widely between individuals. Becky explains why structured eating, hydration, and sufficient protein intake remain important — even when hunger cues are reduced — and why strength training can play a key role in protecting muscle mass during weight loss.
The conversation also explores hormonal considerations, including potential menstrual changes, and the importance of distinguishing GLP-1 side effects from symptoms linked to perimenopause, menopause, or other health conditions. Throughout the discussion, both stress the importance of medical supervision, monitoring symptoms, and seeking professional advice if anything feels unusual or unmanageable.
This episode aims to inform and reassure, helping listeners better understand what may be normal, what to monitor, and how to approach a GLP-1 journey safely.
This content is for information only and does not replace advice from a GP or prescribing clinician.
- Common early body reactions to GLP-1 medications
- Nausea, appetite changes, and reduced food noise
- Digestive effects, hydration, and feeling full for longer
- Fatigue, brain fog, and energy fluctuations
- Muscle loss, strength training, and movement
- Hormonal factors and when to seek medical advice
My Health Focus is not a medical service. The information provided is for general informational purposes only and does not constitute medical advice, diagnosis, or treatment.
JOIN THE MY HEALTH FOCUS COMMUNITY AND SIGN UP TO OUR NEWSLETTER
Hosted on Acast. See acast.com/privacy for more information.